Similarly, Pfizer has invested $500 million to establish a sustainable biotechnology center in Sanford, North Carolina, which will focus on gene therapy manufacturing. And Merck & Co. is partnering with Purdue University to launch an R&D manufacturing consortium to help boost U.S. production.
“The Raleigh region is quickly becoming a hub for pharmaceutical manufacturing, with major companies investing billions of dollars into the area,” said Edgeton. “This influx of investment is creating thousands of jobs and solidifying the region’s reputation as a key player in the biotech industry.”
Overall, the Raleigh region’s strong talent pool, supportive infrastructure, and collaborative ecosystem are attracting pharmaceutical companies looking to expand their manufacturing capabilities in the U.S. The area’s commitment to innovation and investment in workforce development programs are further positioning it as a leader in the biotech sector.
As the trend of onshoring pharmaceutical manufacturing continues to grow, Raleigh is poised to play a significant role in meeting the industry’s increasing demand for domestic production. With its strategic location, skilled workforce, and supportive business environment, the region is well-equipped to capitalize on the opportunities presented by this shift in the pharmaceutical industry.
With the ongoing investments from major pharmaceutical companies and the continued growth of the biotech sector in Raleigh, the region is set to emerge as a key player in the global pharmaceutical manufacturing landscape. The future looks bright for Raleigh as it cements its position as a leading hub for innovation and growth in the biotech industry.
The pharmaceutical manufacturing industry in North Carolina is experiencing a surge of growth, with major companies like Johnson & Johnson and Amgen making significant investments in the region. Johnson & Johnson, a global healthcare giant, is set to build a second fill and finishing manufacturing facility, which is expected to create an additional 1,000 jobs on top of the nearly 2,500 jobs it has already brought to the area.
In addition to Johnson & Johnson’s expansion, the company is also investing $2 billion in a biologics manufacturing facility in Wilson, North Carolina. This facility is projected to add around 420 full-time jobs to the region, further boosting economic development.
Amgen, another leading biotech company, is also contributing to the growth of the pharmaceutical manufacturing sector in North Carolina. The company is investing $1 billion to build a second drug substance manufacturing facility in Holly Springs, creating 370 new jobs and increasing its total investment in the area to over $1.5 billion.
Smaller companies are also joining the wave of expansion, with SCHOTT Pharma USA announcing plans to establish a new production facility in Wilson County. This investment of $371 million will result in the creation of 401 jobs, further solidifying North Carolina’s position as a hub for pharmaceutical manufacturing.
Despite the challenges posed by the COVID-19 pandemic, the pharmaceutical industry in North Carolina has shown resilience and continued growth. With 29 life sciences projects currently in active development, the region is poised for further expansion in the coming years. Companies in the pharma and biotech sectors are increasingly looking to onshore their production, with a growing emphasis on domestic manufacturing capabilities.
The momentum of growth in the pharmaceutical manufacturing industry in North Carolina shows no signs of slowing down. As companies continue to invest in the region and create new job opportunities, the state is establishing itself as a key player in the global pharmaceutical supply chain. With a focus on innovation and production efficiency, North Carolina is well-positioned to drive further growth and development in the pharmaceutical manufacturing sector.
